Going by co announcement the ICS data is due out "early October" which could mean any time now.
Presumably the first thing we'll know about it will be a trading halt for the announcement.
If that ICS data indicates a positive cellular impact, I imagine the rush will be on to accumulate prior to the CAN003 interim trial results.
ICS may actually be the more critical in the long term, as it potentially opens the door for CVAC application to other Mucin1 cancer markets, many of which are bigger than Ovarian Cancer.
calm before storm?, page-30
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
-0.005(1.56%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.8¢ | 31.0¢ | $1.817M | 5.763M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 71665 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 36363 | 2 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |